Cambridge-US alliance fights lung cancer
A collaboration between Cambridge life science company Inivata and US molecular diagnostics company Biodesix, Inc is designed to develop and commercialise next generation sequencing-blood based tests for clinical applications in lung cancer.
The agreement will leverage Inivata’s proprietary, enhanced TAm-Seq technology platform and Boulder, Colorado company Biodesix’ development and commercialisation capabilities in the US market to provide new, clinically actionable tests to physicians.
Inivata and Biodesix will conduct studies in non-small cell lung cancer (NSCLC) using Inivata’s NGS technology platform. Biodesix and Inivata will jointly fund studies to establish clinical utility for an NGS-based test and will initiate an observational study later this year.
Inivata CEO Michael Stocum (pictured above) said: “Approximately 30 per cent of NSCLC patients are unable to obtain a biopsy or have insufficient tissue from a lung cancer biopsy to provide the diagnostic information needed for their care.
“Blood-based diagnostics can make a real difference in such cases. Using Inivata’s circulating tumor DNA (ctDNA) analysis platform, we can now provide information that was previously unattainable for these patients, leading to better outcomes.” said .
Lung cancer is the leading cause of cancer death worldwide. To more effectively understand how NGS-blood-based tests can improve care for patients with lung cancer, Biodesix and Inivata will be working with key opinion leaders and pharmaceutical companies.